ArticleBriefings in functional genomics2025
VirusImmu: a novel ensemble machine learning approach for viral immunogenicity prediction.
Article in Briefings in functional genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- PU-GRAIL: residue-level graph learning for identifying protective bacterial antigens under positive-unlabeled supervision.Bioinformatics (Oxford, England) · 2026Article
- From Neoantigens to Nanocarriers: Modern Methods and Modalities in Using Peptides for Cancer Vaccination.Biochemistry · 2026Review
- NeoTImmuML: a machine learning-based prediction model for human tumor neoantigen immunogenicity.Frontiers in immunology · 2025Article
- Advances of computational methods enhance the development of multi-epitope vaccines.Briefings in bioinformatics · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The viruses threats provoke concerns regarding their sustained epidemic transmission, making the development of vaccines particularly important. In the prolonged and costly process of vaccine development, the most important initial step is to identify protective immunogens. Machine learning (ML) approaches are productive in analyzing big data such as microbial proteomes, and can remarkably reduce the cost of experimental work in developing novel vaccine candidates. We intensively evaluated the B cell epitope immunogenicity prediction power of eight commonly-used ML methods by random sampling cross validation on a large dataset consisting of known viral immunogens and non-immunogens we manually curated from the public domain. Extreme Gradient Boosting, K Nearest Neighbours, and Random Forest) showed the strongest predictive power. We then proposed a novel soft-voting based ensemble approach (VirusImmu), which demonstrated a powerful and stable capability for viral immunogenicity prediction across the test set and external test set irrespective of protein sequence length. VirusImmu was successfully applied to facilitate identifying linear B cell epitopes against African Swine Fever Virus as confirmed by indirect ELISA in vitro. In short, VirusImmu exhibited tremendous potentials in predicting immunogenicity of viral protein segments. It is freely accessible at https://github.com/zhangjbig/VirusImmu.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.